B.Riley Financial Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $92
Buy Rating Affirmed for Cytokinetics Amid Strong Cardiac Myosin Inhibitor Prospects and Positive Market Response
Terreno Realty Analyst Ratings
Jefferies Maintains Cytokinetics(CYTK.US) With Buy Rating, Raises Target Price to $92
Taylor Morrison Home Analyst Ratings
Barclays Maintains Cadence Bancorp(CADE.US) With Hold Rating, Raises Target Price to $33
Barclays Maintains Old National Bancorp(ONB.US) With Buy Rating, Maintains Target Price $22
Barclays Reaffirms Their Buy Rating on Old National Bancorp Capital (ONB)
BTIG Upgrades Taylor Morrison Home(TMHC.US) to Buy Rating, Announces Target Price $78
Wedbush Adjusts Terreno Realty Price Target to $70 From $57, Maintains Neutral Rating
Meritage Homes Analyst Ratings
Wolfe Research Upgrades Meritage Homes to Outperform, Announces $230 Price Target
Wolfe Research Upgrades Meritage Homes to Outperform From Peer Perform, Price Target Is $230
Wolfe Research Upgrades Meritage Homes(MTH.US) to Buy Rating, Announces Target Price $230
Terreno Realty Analyst Ratings
Maintaining Hold on Terreno Realty Amid Balanced Performance and Growth Potential
Cytokinetics Analyst Ratings
Goldman Sachs Downgrades Cytokinetics to Neutral, Lowers Price Target to $60
Cytokinetics: Hold Rating With Neutral Outlook Amid Regulatory and Market Predictability
Terreno Realty (TRNO) Receives a Buy From JMP Securities